-+ 0.00%
-+ 0.00%
-+ 0.00%

Grand Pharmaceutical Group’s TLX591-CDx Achieves Primary Endpoint in China Phase III Prostate Cancer Trial

路透·12/21/2025 10:05:47

登錄查看新聞詳情